The Safety Profile of COVID-19 Vaccines in Patients Diagnosed with Multiple Sclerosis: A Retrospective Observational Study
暂无分享,去创建一个
C. Scavone | A. Capuano | Giuseppe Russo | V. Manzo | A. Falco | G. Maniscalco | E. Prestipino | S. Cozzolino | A. Mascolo | V. Andreone | G. Guglielmi | A. Bracco | Massimo Majolo | A. Ziello | Marida Massa | E. Raiola | G. Longo | M. Aiezza | O. Moreggia | Daniele Di Giulio Cesare | Roberto Soprano
[1] V. De Rosa,et al. Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects , 2021, Multiple Sclerosis and Related Disorders.
[2] G. Kampf. The epidemiological relevance of the COVID-19-vaccinated population is increasing , 2021, The Lancet Regional Health - Europe.
[3] V. Tomassini,et al. Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases , 2021, Frontiers in Neurology.
[4] M. Verma,et al. Effectiveness of COVID-19 vaccine in preventing infection and disease severity: a case-control study from an Eastern State of India , 2021, Epidemiology and Infection.
[5] V. Tomassini,et al. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.
[6] M. D. Di Battista,et al. Severe Multiple Sclerosis Relapse After COVID-19 Vaccination: A Case Report , 2021, Frontiers in Neurology.
[7] I. Lotan,et al. Safety of the BNT162b2 COVID‐19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel , 2021, European journal of neurology.
[8] M. Ulivelli,et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies , 2021, EBioMedicine.
[9] M. D. Di Battista,et al. Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study , 2021, Brain sciences.
[10] M. Etemadifar,et al. Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient , 2021, Human vaccines & immunotherapeutics.
[11] A. Achiron,et al. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021 , 2021, Multiple sclerosis.
[12] S. Chilimuri,et al. COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab , 2021, Vaccines.
[13] M. Sormani,et al. Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis , 2021, Annals of neurology.
[14] L. Berrino,et al. Therapeutic strategies to fight COVID‐19: Which is the status artis? , 2021, British journal of pharmacology.
[15] Nguyen H. Tran,et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.
[16] X. Montalban,et al. COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response , 2020, European journal of neurology.
[17] G. Tedeschi,et al. Preliminary Results of the FASM Study, an On-Going Italian Active Pharmacovigilance Project , 2020, Pharmaceuticals.
[18] P. Dormitzer,et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.
[19] N. Mercuri,et al. Adherence to social distancing and use of personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with multiple sclerosis , 2020, Multiple Sclerosis and Related Disorders.
[20] G. Racagni,et al. NSAIDs in patients with viral infections, including Covid-19: Victims or perpetrators? , 2020, Pharmacological Research.
[21] L. Berrino,et al. Current pharmacological treatments for COVID‐19: What's next? , 2020, British journal of pharmacology.
[22] C. Scavone,et al. SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment , 2020, International Immunopharmacology.
[23] L. Berrino,et al. Current pharmacological treatments for COVID‐19: What's next? , 2020, British journal of pharmacology.
[24] C. Scavone,et al. Surveillance of adverse events following immunization related to human papillomavirus vaccines: 12 years of vaccinovigilance in Southern Italy , 2019, Expert opinion on drug safety.
[25] J. Correale,et al. The role of infections in multiple sclerosis , 2019, Multiple sclerosis.
[26] G. Alter,et al. Sex differences in vaccine-induced humoral immunity , 2018, Seminars in Immunopathology.
[27] C. Scavone,et al. Did the New Italian Law on Mandatory Vaccines Affect Adverse Event Following Immunization’s Reporting? A Pharmacovigilance Study in Southern Italy , 2018, Front. Pharmacol..
[28] L. Walker,et al. T Cell/B Cell Collaboration and Autoimmunity: An Intimate Relationship , 2018, Front. Immunol..
[29] R. Gold,et al. Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010 , 2018, CNS Drugs.
[30] C. Scavone,et al. Drugs approved for the treatment of multiple sclerosis: review of their safety profile , 2017, Expert opinion on drug safety.
[31] S. Deeks,et al. Assessment of sex-specific differences in adverse events following immunization reporting in Ontario, 2012-15. , 2017, Vaccine.
[32] M. T. Pellecchia,et al. Quitting smoking: an early non-motor feature of Parkinson's disease? , 2015, Parkinsonism & related disorders.
[33] E. Russo,et al. Pharmacovigilance in Italy: An overview , 2013, Journal of pharmacology & pharmacotherapeutics.
[34] Hanne F. Harbo,et al. Sex and gender issues in multiple sclerosis , 2013, Therapeutic advances in neurological disorders.
[35] M. Tullman,et al. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. , 2013, The American journal of managed care.
[36] Stavros J. Baloyannis,et al. Epidemiology of multiple sclerosis in Europe: A Review , 2010, International review of psychiatry.
[37] T. Dwyer,et al. Monthly Ambient Sunlight, Infections and Relapse Rates in Multiple Sclerosis , 2008, Neuroepidemiology.
[38] J. Correale,et al. The risk of relapses in multiple sclerosis during systemic infections , 2006, Neurology.
[39] T. Bergström,et al. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study , 1993, Journal of Neurology.
[40] A. Alpérovitch,et al. CLINICAL VIRAL INFECTIONS AND MULTIPLE SCLEROSIS , 1985, The Lancet.
[41] W. Sibley,et al. CLINICAL VIRAL INFECTIONS AND MULTIPLE SCLEROSIS , 1985, The Lancet.